Article
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Thoracic cancer - 1 Jan 2023
Chang John Wen-Cheng, Huang Chen-Yang, Fang Yueh-Fu, Chang Ching-Fu, Yang Cheng-Ta, Kuo Chih-Hsi Scott, Hsu Ping-Chih, Wu Chiao-En
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. This study aimed to evaluate the efficacy of EGFR-TKIs and prognostic factors for patients with NSCLC harboring uncommon EGFR mutations, which account for 10% of EGFR mutations. METHODS: A total of 230 treatment-naive patients...
Topics
- Humans
- Carcinoma, Non-Small-Cell Lung
- Afatinib
- Gefitinib
- Erlotinib Hydrochloride
- Tyrosine Kinase Inhibitors
- Lung Neoplasms
- Retrospective Studies
- Taiwan
- Protein Kinase Inhibitors